In2Pharma
  • Home
  • Services
    • Regulatory Affairs
    • Quality Assurance
    • Publicity and Compliance
    • Medical writing & training
    • Vigilance
  • About Us
  • News
  • Contact
Select Page
Falsified Medicines Directive: end of transition period and beginning of monitoring activities

Falsified Medicines Directive: end of transition period and beginning of monitoring activities

by In2Pharma | Nov 4, 2019 | News

Belgium From 9 February  2019, all prescription and reimbursable medicines on the market must bear safety features. At each link in the distribution chain, the safety features must be checked so that the authenticity of the medicine upon delivery can be guaranteed....

Recent Posts

  • Junior Consultant vacancy
  • Register your Industry Single Point of Contact (i-SPOC) on supply and availability
  • Update Commission Regulation regarding monacolins from red yeast rice
  • The FAMHP launches the Medicinal Product Management database
  • Request to marketing authorisation holders to send the approved version of the risk management plan

Follow Us

  • Facebook
  • LinkedIn
Privacy Policy | Cookie Policy | BTW BE 895730662 | +32 16 89 16 00| info@in2pharma.com | Terloonststraat 22, 1910 Kampenhout, België